Xencor, Inc. (XNCR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Xencor, Inc. (XNCR) Healthcare & Pipeline Overview

Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in engineered monoclonal antibodies and cytokine therapeutics for cancer and autoimmune diseases. Their XmAb platform differentiates them in a competitive market, with multiple clinical trials underway and strategic partnerships driving growth. The company operates within the rapidly evolving biotechnology sector.

What Is the Investment Thesis for XNCR?

Xencor's investment thesis hinges on its proprietary XmAb technology platform and its ability to generate a diverse pipeline of novel antibody and cytokine therapeutics. The company's clinical-stage programs, particularly Plamotamab and Vudalimab, represent significant potential value drivers. Successful clinical trial outcomes and subsequent regulatory approvals could lead to substantial revenue growth. Xencor's gross margin of 94.4% indicates strong profitability potential for approved products. However, the company's negative profit margin of -185.7% reflects significant ongoing R&D expenses. Key risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's beta of 0.99 suggests market-average volatility. Upcoming clinical trial readouts for key pipeline assets will be critical catalysts.

Based on FMP financials and quantitative analysis

XNCR Key Highlights

• Market capitalization of $1.47B reflects investor valuation of Xencor's pipeline and technology.
• Gross margin of 94.4% demonstrates strong potential profitability of approved products.
• Negative profit margin of -185.7% indicates significant investment in research and development.
• Beta of 0.99 suggests market-average volatility compared to the broader market.
• Extensive pipeline with multiple programs in Phase 1 and Phase 2 clinical trials indicates potential for future growth.

Who Are XNCR's Competitors?

XNCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XNCR's Key Strengths?

• Proprietary XmAb technology platform.
• Diverse pipeline of clinical-stage programs.
• Strong partnerships with pharmaceutical companies.
• High gross margin potential.

What Are XNCR's Weaknesses?

• Negative profit margin due to high R&D expenses.
• Reliance on clinical trial success.
• Competition from larger pharmaceutical companies.
• Dependence on key partnerships.

What Could Drive XNCR Stock Higher?

• Phase II clinical trial results for Vudalimab in metastatic castration-resistant prostate cancer (2027).
• Phase I clinical trial results for XmAb306 in solid tumors (2027).
• Continued development of Plamotamab in Phase I clinical trial for non-Hodgkin lymphoma.
• Advancement of Tidutamab in Phase II clinical trial for neuroendocrine tumors.
• Potential new partnerships or licensing agreements for XmAb platform technologies.

What Are the Key Risks for XNCR?

• Negative return on equity (-28.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key pipeline assets.
• Regulatory delays or rejection of marketing applications.
• Competition from other biotechnology companies developing similar therapies.
• Dependence on key partnerships for revenue generation.
• High R&D expenses impacting profitability.

What Are the Growth Opportunities for XNCR?

• Expansion of Plamotamab Development: Plamotamab, a tumor-targeted antibody in Phase I clinical trial for non-Hodgkin lymphoma, represents a significant growth opportunity. The market for non-Hodgkin lymphoma therapeutics is projected to reach $12.8 billion by 2028. Positive clinical trial results and subsequent regulatory approval could drive substantial revenue growth for Xencor. The company's XmAb platform allows for the optimization of Plamotamab's efficacy and safety profile, providing a competitive advantage.
• Advancement of Vudalimab Program: Vudalimab, a bispecific antibody in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumors, offers another key growth driver. The prostate cancer therapeutics market is expected to reach $12 billion by 2027. Successful clinical development and commercialization of Vudalimab could significantly increase Xencor's market share. The bispecific antibody format enhances Vudalimab's ability to target and eliminate tumor cells.
• Development of Tidutamab for Neuroendocrine Tumors: Tidutamab, currently in Phase II clinical trial for neuroendocrine tumors, presents a targeted growth opportunity. The neuroendocrine tumor therapeutics market is estimated at $1.8 billion. Positive trial outcomes could lead to regulatory approval and commercial success. Xencor's antibody engineering expertise contributes to Tidutamab's potential efficacy and safety.
• Partnerships and Licensing Agreements: Xencor's collaborations with pharmaceutical companies like Novartis and its license agreement with Caris Life Sciences provide opportunities for revenue generation and pipeline expansion. These partnerships allow Xencor to leverage external resources and expertise, accelerating the development and commercialization of its therapeutics. Strategic alliances can also provide non-dilutive funding for research and development activities.
• Expansion into New Therapeutic Areas: Xencor's XmAb platform can be applied to a wide range of therapeutic areas beyond cancer and autoimmune diseases. Exploring new indications, such as infectious diseases or neurological disorders, could unlock additional growth opportunities. The company's expertise in antibody engineering and cytokine therapeutics positions it well to address unmet medical needs in diverse disease areas. This strategic diversification could mitigate risks associated with reliance on specific therapeutic markets.

What Opportunities Does XNCR Have?

• Expansion into new therapeutic areas.
• Advancement of pipeline programs through clinical trials.
• Strategic acquisitions or licensing deals.
• Increased adoption of antibody therapeutics.

What Threats Does XNCR Face?

• Clinical trial failures.
• Regulatory hurdles.
• Patent expirations.
• Competition from biosimilars.

What Are XNCR's Competitive Advantages?

• Proprietary XmAb technology platform for antibody engineering.
• Extensive patent portfolio protecting its antibody technologies and therapeutic candidates.
• Expertise in cytokine engineering and bispecific antibody development.
• Established partnerships with major pharmaceutical companies.

What Does XNCR Do?

Xencor, Inc., founded in 1997 and headquartered in Monrovia, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing engineered monoclonal antibody and cytokine therapeutics. The company's core technology, the XmAb platform, allows for the creation of novel antibody and cytokine therapies with improved efficacy, safety, and manufacturability. Xencor's pipeline includes a range of programs targeting cancer and autoimmune diseases. Key products and programs include Sotrovimab (targeting SARS-CoV-2), Ultomiris (for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome), and Monjuvi (for relapsed or refractory diffuse large B-cell lymphoma). Additionally, Xencor is developing Plamotamab (Phase I, non-Hodgkin lymphoma), Vudalimab (Phase II, metastatic castration-resistant prostate cancer and other solid tumors), and Tidutamab (Phase II, neuroendocrine tumors). The company also has several other programs in Phase I clinical trials, including XmAb306, XmAb104, XmAb841, XmAb564, AMG 509, and XmAb819. Xencor collaborates with other pharmaceutical companies, including Novartis, and has a license agreement with Caris Life Sciences. Xencor's strategic focus on innovative antibody engineering positions it within the competitive biotechnology landscape.

What Products and Services Does XNCR Offer?

• Discovers and develops engineered monoclonal antibody therapeutics.
• Creates cytokine therapeutics for cancer and autoimmune diseases.
• Utilizes the XmAb platform to improve antibody efficacy, safety, and manufacturability.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval for its therapeutics from agencies like the FDA.
• Commercializes approved therapeutics through its own sales force or partnerships.
• Collaborates with other pharmaceutical companies to develop and market new therapies.

How Does XNCR Make Money?

• Develops and out-licenses antibody technologies.
• Generates revenue through milestone payments and royalties on partnered programs.
• Commercializes proprietary therapeutics directly.
• Focuses on high-value therapeutic areas with unmet medical needs.

What Industry Does XNCR Operate In?

Xencor operates within the biotechnology industry, a sector characterized by high growth potential and substantial risk. The market for antibody therapeutics is expanding, driven by advances in protein engineering and a growing understanding of disease mechanisms. Competition is intense, with numerous companies developing novel therapies for cancer and autoimmune diseases. Xencor's XmAb platform provides a competitive advantage by enabling the creation of differentiated antibody therapeutics. The biotechnology industry is subject to stringent regulatory oversight and faces challenges related to clinical trial success and market access.

Who Are XNCR's Key Customers?

• Patients with cancer and autoimmune diseases.
• Pharmaceutical companies seeking to license or partner on novel antibody therapeutics.
• Healthcare providers who prescribe Xencor's approved therapies.
• Research institutions collaborating on drug discovery and development.

How Xencor, Inc. Is Valued

Xencor, Inc. carries a market capitalization of $1.47B, placing it in the small-cap category. Relative to its peer group, XNCR's quantitative score of 23/100 is below the peer average of 75/100.

Company Profile

Xencor, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pasadena, US. The company is led by CEO Bassil I. Dahiyat. XNCR has traded publicly since 2013.

ROE -29%Key Financial Metrics

Return on equity for Xencor, Inc. stands at -28.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Xencor, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.31 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project Xencor, Inc. revenue of about $72.7M for fiscal 2026, with EPS near $-3.88. The estimate reflects 10 contributing analysts.

Net buyingInsider Activity

Over the past six months, Xencor, Inc. insiders filed 30 SEC Form 4 transactions — 13 sales and 17 purchases. On net that is roughly 203K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

XNCR Financials

XNCR Latest News

XNCR Analyst Consensus

XNCR MoonshotScore

What Investors Ask About Xencor, Inc. (XNCR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources